Business
Merck to Complete Acquisition of Cidara Therapeutics
RAHWAY, N.J., January 07, 2026--Merck to Complete Acquisition of Cidara Therapeutics
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/bcf4baf8584f1d548ba01176a4b5786a"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/1t.E5jAM20OaVDmIYVyirA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/bcf4baf8584f1d548ba01176a4b5786a","width":480,"height":217}},"lazy":false},{"type":"text","content":"RAHWAY, N.J., January 07, 2026--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all the outstanding shares of common stock of Cidara Therapeutics, Inc. (Nasdaq: CDTX) ("Cidara").","length":324,"tagName":"p"},{"type":"text","content":""The acquisition of Cidara strengthens and complements our expanding respiratory portfolio and exemplifies our business development strategy of investing where compelling science and value meet," said Robert M. Davis, chairman and chief executive officer, Merck. "CD388, a potentially first-in-class, long-acting antiviral with strain-agnostic properties, underscores that approach. We look forward to building on Cidara’s progress and further evaluating the potential of this candidate for the prevention of symptomatic influenza in certain individuals at high risk of complications."","length":605,"tagName":"p"},{"type":"text","content":"Merck completed the cash offer at a purchase price of $221.50 per share of common stock of Cidara, without interest and subject to deduction for any required tax withholding. As of the tender offer expiration at one minute after 11:59 p.m., Eastern Time, on January 6, 2026, 27,149,333 shares of common stock were validly tendered and not withdrawn, representing approximately 85.96% of the total number of Cidara’s issued and outstanding shares of common stock. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck expects to promptly pay for such shares.","length":610,"tagName":"p"},{"type":"text","content":"Merck intends to complete today the acquisition through a merger of Merck’s wholly owned subsidiary with and into Cidara, with Cidara being the surviving cor...